Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], a type of cholesterol-related particle linked to cardiovascular risk.
Lipoprotein Study
Age Range:
18
Gender:
Male and Female
Location:
Rochester, New York
About the Study
This research study is evaluating an investigational study medication called muvalaplin. The purpose is to assess whether muvalaplin can help reduce the risk of major adverse cardiovascular events in adults with elevated Lp(a) who have either had a prior atherosclerotic cardiovascular event or are at risk for a first cardiovascular event.
Qualifications
You may be able to join if you:
- Are 18 years of age or older.
- Have elevated Lp(a) based on study testing.
- Have had a prior cardiovascular event, or have risk factors that may place you at risk for a first cardiovascular event.
- Are willing to attend study visits and follow study procedures for the duration of the study.
- Are on stable doses of certain cholesterol-lowering medications, if applicable.
- Do not have a recent major cardiovascular event, such as heart attack or stroke.
- Do not have uncontrolled high blood pressure, severe kidney problems, or certain other serious medical conditions.
- Are not currently pregnant or breastfeeding.
FEATURED STUDIES
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]
Adults 18 and older who have had daily moderate to severe low back pain for at least 3 months may […]
Adults living with obesity, or overweight with a weight-related health condition, may qualify for a clinical research study evaluating an […]
Adults 18 years and older with overweight or obesity and without type 2 diabetes may qualify for a study evaluating […]
Adults with osteoarthritis (OA) knee pain may qualify for a research study evaluating an investigational medication for chronic pain relief.
Adults 18 to 75 years of age may qualify for a research study evaluating an investigational medication for migraine attacks.